Get started
Work

264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2023
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2023.10.390
Authors: W.K. Kelly, D.C. Danila, C-C. Lin, J-L. Lee, N. Matsubara, P.J. Ward, A.J. Armstrong, D.W. Pook, M. Kim, T. Dorff, S. Fischer, Y-C. Lin, L.G. Horvath, C. Sumey, Z. Yang, G. Jurida, J. Connarn, H. Penny, J. Stieglmaier, L.J. Appleman
Institutions: Thomas Jefferson University, Memorial Sloan Kettering Cancer Center, National Taiwan University Hospital, Asan Medical Center, University of Ulsan, National Cancer Center Hospital East, Oncology Hematology Care, Duke University, Duke Cancer Institute, Monash Medical Centre, Seoul National University, Seoul National University Hospital, City Of Hope National Medical Center, City of Hope, Kantonsspital St. Gallen, Linkou Chang Gung Memorial Hospital, The University of Sydney, Chris O’Brien Lifehouse, Sanford Health, Amgen (United States), Amgen (Germany), UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: U.S. Department of Defense, Prostate Cancer Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Celgene, Memorial Sloan-Kettering Cancer Center, Karyopharm Therapeutics, Endocyte, Regeneron Pharmaceuticals, Merck KGaA, Exelixis, INOVIO Pharmaceuticals, BeiGene, Calithera Biosciences, Yuhan, Seagen, Eisai, Astellas Pharma, Ono Pharmaceutical, Ipsen, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Genentech, Chugai Pharmaceutical, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4389280670
FWCI: 0.184
Cites:
Cited by: 1
Related to: 10